Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo’s new China presidentnews2026-03-06T12:00:41+00:00March 6th, 2026|Endpoints News|
FDA official questions need for advisory committeesnews2026-03-06T01:46:00+00:00March 6th, 2026|Endpoints News|
Kura says its menin inhibitor is preferred treatment for some payersnews2026-03-05T20:34:01+00:00March 5th, 2026|Endpoints News|
Roche partner Zealand posts Phase 2 data for amylin obesity drugnews2026-03-05T20:19:31+00:00March 5th, 2026|Endpoints News|
Roche, Element and Ultima push toward the $100 genomenews2026-03-05T20:17:26+00:00March 5th, 2026|Endpoints News|
FDA approves J&J’s multiple myeloma combo as second-line treatmentnews2026-03-05T19:59:40+00:00March 5th, 2026|Endpoints News|
New FDA bonus pilot to address ‘workforce challenges’news2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Helus Pharma’s stock slides after psychedelic drug data face questions over dosingnews2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Eli Lilly’s new program aims to boost employer coverage of GLP-1snews2026-03-05T17:02:54+00:00March 5th, 2026|Endpoints News|
Tenaya wins support from Alnylam in cardio disease pactnews2026-03-05T16:06:00+00:00March 5th, 2026|Endpoints News|
